公开(公告)号：US20170067115A1

公开(公告)日：2017-03-09

申请号：US15120052

申请日：2015-02-18

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Lucia PEREZ-CARBONELL ,  C. Richard BOLAND

IPC: C12Q1/68 ,  C12N15/113 ,  G06F19/00 ,  A61K31/513

CPC classification number: C12Q1/6886 ,  A61K31/513 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G06F19/00 ,  G16H10/60 ,  G16H40/63 ,  Y02A90/22 ,  Y02A90/26

Abstract: Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying miRNAs that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer. Methods and compositions are based, in part, on the discovery that expression of certain miRNAs in cancer patients is associated with advancing cancer stages and/or can predict the responsiveness of cancer therapy, and can, therefore, provide basis for designing treatment strategies. In particular embodiments, the miRNA molecule is miR-320, particularly miR-320e.

Abstract translation: 实施例提供了通过检测和分析患者诸如miR-320e之类的miRNA的表达水平来确定结肠直肠癌患者治疗相关的方法和组合物。 实施例通过鉴定可用于临床治疗癌症患者，特别是结肠直肠癌患者或处于风险中或确定为结肠直肠癌的患者的miRNA来提供预测，预后和/或诊断方法。 方法和组合部分地基于发现癌症患者中某些miRNA的表达与癌症阶段的进展和/或可以预测癌症治疗的反应性相关联，并且因此可以为设计治疗策略提供依据。 在具体实施方案中，miRNA分子是miR-320，特别是miR-320e。

公开(公告)号：US20210139992A1

公开(公告)日：2021-05-13

申请号：US16492524

申请日：2018-03-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Daisuke IZUMI

IPC: C12Q1/6886

Abstract: Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for gastric cancer patients.

公开(公告)号：US20180298386A1

公开(公告)日：2018-10-18

申请号：US15559362

申请日：2016-03-17

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Kunitoshi SHIGEYASU

IPC: C12N15/113 ,  A61P35/00 ,  C07K16/28 ,  A61P35/04 ,  G01N33/574 ,  C07K16/32 ,  C12Q1/6886

CPC classification number: C12N15/1138 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/713 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28 ,  C07K16/32 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2800/56

Abstract: Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMCO3. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMCO3 level relative to a control or a reference level that is normal or indicating favorable prognosis.

公开(公告)号：US20190185944A1

公开(公告)日：2019-06-20

申请号：US16322380

申请日：2017-08-04

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Jinsei MIYOSHI

IPC: C12Q1/6886 ,  C12Q1/02 ,  A61K31/337 ,  A61K31/351 ,  A61K33/243 ,  A61K31/513 ,  A61P35/04

CPC classification number: C12Q1/6886 ,  A61K31/337 ,  A61K31/351 ,  A61K31/513 ,  A61K33/243 ,  A61P35/04 ,  C12Q1/025 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: The current disclosure relates to therapeutic treatments and diagnostic methods for esophageal cancer based on the expression level of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, said method comprising: diagnosing the patient with esophageal cancer when the patient is determined to have an elevated or decreased level of expression of one or more miRNAs selected from mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i in a sample from a patient relative to the expression level of the one or more miRNAs in a control sample; and administering an effective amount of an esophageal treatment to the diagnosed patient.